Progressing From Metformin to Sulfonylureas or Meglitinides.
The article provides an overview of sulfonylureas and meglitinides as second-line agents for treating type 2 diabetes mellitus (T2DM). Implications for occupational health clinicians who work with these individuals when they take either of these medications to achieve target glycemic indices are emphasized.
The University of Alabama at Birmingham grantj@uab.edu.
Joan S
JS
Grant
Florida State University.
Lucinda J
LJ
Graven
D000367:Age Factors; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D038321:Glycemic Index; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008687:Metformin / Q000008:administration & dosage* / Q000009:adverse effects; D016272:Occupational Health; D009785:Occupational Health Nursing / Q000379:methods*; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects
D001549:Benzamides; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C030516:meglitinide; D008687:Metformin
meglitinides; metformin; sulfonylureas; type 2 diabetes mellitus